ByteDance Spins Off AI Drug Discovery Unit Anew Labs in $290M Round
ByteDance has spun off its Shanghai-based AI drug discovery unit, Anew Labs, securing $290 million in financing at a $1.5 billion valuation. The funding round was led by major investors including HSG, IDG Capital, and Hillhouse Investment, with ByteDance retaining a 56% controlling stake. This deal underscores how major tech conglomerates are leveraging consumer AI infrastructure to address complex life science challenges while granting specialized units distinct operational independence. It also demonstrates strong venture capital confidence in AI-driven biotechnology. The spin-off was driven by the distinct operational logic and management styles required in pharmaceuticals compared to ByteDance's core internet business. Additional backers include co-lead investor 5Y Capital, along with Gaorong Ventures, Primavera Capital, Boyu Capital, SBP Group, and the state-backed Shanghai Future Industry Fund.
## BACKGROUND
Traditional drug discovery is traditionally expensive, time-consuming, and carries high failure rates before candidates reach clinical trials. AI-driven drug discovery utilizes machine learning models and biological datasets to predict molecular structures, identify targets, and significantly accelerate therapeutic development timelines.